China Regenerative Medicine International is a tissue engineering company. With only 5,000 corneas donated each year for transplants, millions of Chinese citizens who need a cornea transplant to regain their eyesight have been forced to wait--or give up hope. But since 2000, CRMI has been working on an artificial cornea that could be used instead of donated ones. It landed on an unprecedented idea--to use pigs' corneas, rather than constructing wholly artificial ones--and in 2013 clinical trials, they produced stunning results, with more than 90% of patients responding well to the surgery. In 2015, the China Food and Drug Administration approved the artificial corneas for widespread use, and CRMI began mass production in July. CRMI also announced a partnership with China Resources Healthcare Group in August, which should help the company bring its groundbreaking product to hospitals and providers. The partnership will also provide a platform to promote its other regenerative products, which focus on skin and cartilage.